Search
for
Sort by
Research
690-720 / 1000+ results research 699 Pharmacological blockade of the CX3CR1/CX3CL1 fractalkine axis prevents alopecia areata in C3H/HeJ mice
research Case report: Dupilumab therapy for alopecia areata in a 4-year-old patient resistant to baricitinib
Dupilumab helped a 4-year-old grow hair back after another treatment failed.
research Gene detection in a family with monilethrix and treatment with 5% topical minoxidil
5% topical minoxidil improves hair density and quality in monilethrix patients.
research Nonsteroidal inhibitors of human type I steroid 5-.alpha.-reductase
New compounds called benzoquinolinones may treat conditions linked to excess DHT.
research First drug for severe alopecia recommended by NICE could benefit 14,000 patients
Ritlecitinib can help about 14,000 people with severe hair loss.
research Investigating tralokinumab-related adverse events in treating atopic dermatitis: insights from the FAERS database
research 153 Effectiveness of OR-101, a next generation highly selective JAK3 inhibitor, in a humanized murine model of alopecia areata
OR-101 shows promise for treating alopecia areata by improving hair growth.
research Trichomegaly of the Eyelashes After Treatment with Erlotinib in Non-small Cell Lung Cancer
A cancer patient's eyelashes grew excessively without other common side effects after taking the cancer drug erlotinib.
research Monilethrix treated with the oral retinoid Ro 10-9359 (Tigason)
Tigason improved hair growth in a boy with monilethrix without side effects.
research A local drug delivery system based on visible light-cured glycol chitosan and doxorubicin⋅hydrochloride for thyroid cancer treatment in vitro and in vivo
GC10/DOX hydrogel shows promise as an effective thyroid cancer treatment.
research Dermatologic adverse events in pediatric patients receiving targeted anticancer therapies: A pooled analysis
Targeted anticancer therapies in children often cause skin side effects like rash and dry skin.
research Sorafenib-induced eruption resembling pityriasis rubra pilaris
A man developed a rash similar to pityriasis rubra pilaris after starting sorafenib for cancer, possibly due to the drug's effect on skin cells.
research Experience with sonidegib in patients with advanced basal cell carcinoma: case reports
Sonidegib effectively treated advanced basal cell carcinoma with mild side effects.
research Lymphoma Specialists Lament the Discontinuation of Underprescribed Bexxar
Oncology specialists are disappointed by the discontinuation of the effective lymphoma treatment Bexxar.
research Comparison of pemetrexed and docetaxel as salvage chemotherapy for the treatment for nonsmall-cell lung cancer after the failure of epidermal growth factor receptor-tyrosine kinase inhibitors
Pemetrexed is as effective as docetaxel but has fewer side effects for treating nonsmall-cell lung cancer after EGFR-TKI therapy failure.
research Treatment of Steroid-Resistant Beard-Restricted Alopecia Areata with Baricitinib
Baricitinib helped treat a man's beard hair loss when steroids didn't work.
research In Vitro and In Vivo Assessment of Metabolic Drug Interaction Potential of Dutasteride with Ketoconazole
Taking Dutasteride with Ketoconazole can increase Dutasteride's effects and side effects.
research A retrospective study of oral tofacitinib therapy for alopecia areata
research P56 Azathioprine-induced alopecia totalis and knuckle hyperpigmentation in a child with uveitis: test before you leap!
Monitor for early signs of azathioprine toxicity and check blood counts regularly.
research Efficacy and safety of docetaxel in the elderly
Docetaxel is safe and works well for older people with cancer, with manageable side effects.
research JAK Inhibitors for Treatment of Alopecia Areata
JAK inhibitors can effectively reverse hair loss in people with alopecia areata.
research Comparison of efficacy and safety of tofacitinib and azathioprine in patients with alopecia areata and variants: a double-blind, randomized controlled trial
research Irish dermatologists’ experience with JAK inhibitors in alopecia areata
Irish dermatologists use JAK inhibitors for alopecia areata but want standardized treatment guidelines.
research Integrated safety analysis of baricitinib in adults with severe alopecia areata from two randomized clinical trials
Baricitinib for severe alopecia areata is generally safe, with common side effects like infections and acne, and low rates of serious complications.
research 331 An open label clinical trial of the JAK inhibitor tofacitinib for alopecia areata
Tofacitinib helped over half of the patients with severe hair loss regrow at least 50% of their hair.
research The pharmacovigilance analysis of adverse events of erlotinib based on the open access FAERS database
Erlotinib can cause unexpected side effects like eyelash growth and scarring.
research Alopecia areata is driven by cytotoxic T lymphocytes and is reversed by JAK inhibition
Alopecia areata can be reversed by JAK inhibitors, promoting hair regrowth.
research Sexual adverse events-related to dutasteride e finasteride: Analysis of real-life data from EudraVigilance database
research The Good and Bad News About New Drugs for Treating Alopecia Areata
JAK inhibitors show promise for treating Alopecia Areata, while statins are not recommended.